Measurement of chemotherapy-induced alopecia—time to change

Supportive Care in Cancer

Volumn 23, Issue 5, 2015, Pages 1197-1199

  van den Hurk, C J G ^a   Winstanley, J ^b   Young, A ^c   Boyle, F ^b  

^a Netherlands Comprehensive Cancer Organization   (Netherlands)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Alopecia; Chemotherapy; Data quality; Side effect

Indexed keywords

ANTINEOPLASTIC AGENT;

ALOPECIA; BODY IMAGE; CHEMICALLY INDUCED; HUMAN; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRE; TIME;

ALOPECIA; ANTINEOPLASTIC AGENTS; BODY IMAGE; HUMANS; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 84931049086     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2647-3     Document Type: Article

References (17)

1. Rosman S (2004) Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 52(3):333–339
2. World Health Organisation (1979) Handbook for reporting results of cancer treatment, vol 48. WHO Offset Publ, Geneva
3. Institute NC (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
4. van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255–3260
5. Breed WPM, van den Hurk CJG, Peerbooms M (2011) Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations. Expert Rev Dermatol 6:109–125
6. Peerbooms M, Breed WPM, van den Hurk CJG (2015 (accepted for publication)) Familiarity, opinions, experiences and knowledge about scalp cooling—a Dutch survey among breast cancer patients and oncological professionals. Asia-Pacific J Oncol Nursing
7. Hurk van den CJG (2013) Safety and effectiveness of scalp cooling in cancer patients undergoing cytotoxic treatment. Thesis. Leiden University Medical Center. Leiden
8. Mulders M, Vingerhoets A, Breed W (2008) The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs 12(2):97–102
9. Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S (2008) Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. Psycho-Oncology 17(6):577–583
10. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP (2010) Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psycho-Oncology 19(7):701–709
11. Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R (2001) Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol 19(8):2213–2221
12. Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T (2005) Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol 23(7):1401–1408
13. Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Tosello C, Viaro D, Zielinski C (1997) Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 8(2):155–162
14. van den Hurk CJ, van den Akker-van Marle ME, Breed WP, van de Poll-Franse LV, Nortier JW, Coebergh JW (2014) Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia. Acta Oncol 53(1):80–87
15. Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, Guillot B, Romieu G, Bessis D (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884
16. Vleut RE, van Poppel JE, Dercksen MW, Peerbooms M, Houterman S, Breed WP (2013) Hair mass index obtained by cross-section trichometry: an objective and clinically useful parameter to quantify hair in chemotherapy-induced alopecia. Support Care Cancer 21(7):1807–1814
17. Kuderer NM, Wolff AC (2014) Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol 32(19):1990–1993